Development and Evolution of DNA-Dependent Protein Kinase Inhibitors toward Cancer Therapy

Area of Science:

• Molecular Biology
• Cancer Therapeutics
• DNA Repair Mechanisms

Background:

• DNA double-strand breaks (DSBs) are critical DNA lesions induced by ionizing radiation and certain chemotherapeutics.
• DNA-dependent protein kinase (DNA-PK) is essential for sensing DSBs and orchestrating their repair via non-homologous end joining (NHEJ).
• Deficiency or inhibition of DNA-PK leads to increased cellular sensitivity to DNA-damaging agents.

Purpose of the Study:

• To review the development and evolution of small molecule inhibitors targeting DNA-PK.
• To highlight the role of these inhibitors in cancer therapy, particularly in combination with radiotherapy and chemotherapy.

Main Methods:

• Review of literature on DNA-PK inhibitors.
• Analysis of inhibitor development strategies based on structural similarities to PI3K and PIKK family kinases.
• Examination of established and emerging DNA-PK inhibitors.

Main Results:

• Numerous small molecules inhibiting DNA-PK have been developed.
• Inhibitor design often leverages structural homology between DNA-PK and related kinases like ATM.
• Specific inhibitors (e.g., NU7026, NU7441) are widely used in research, while newer agents (e.g., M3814, AZD7648) are progressing into clinical trials.

Conclusions:

• DNA-PK inhibitors represent a promising strategy to enhance the efficacy of cancer treatments.
• The clinical advancement of novel DNA-PK inhibitors signifies their potential therapeutic value in oncology.
• Targeting DNA-PK offers a viable approach to sensitize tumors to conventional therapies like radiation and chemotherapy.